Transarterial Chemoembolization in Treatment of Inoperable Patients with Nodular Cholangiocarcinoma
https://doi.org/10.16931/1995-5464.2015324-30
Abstract
Aim. To estimate the efficacy of transarterial chemoembolization (TACE) in treatment of non-surgical patients with nodular cholangiocarcinoma.
Materials and Methods. TACE procedures have been performed in 33 non-surgical patients with cholangiocarcinoma. In 27 (81,8%) patients selective hepatic propria or lobar artery catheterization was apllied, while additional six patients underwent segmental or lobar hepatic arteries microcatheterization.
Results. There were no post-TACE mortality or severe morbidity. Twenty eight out of 33 treated patients were available for long-term survival analysis. Eight (28.6%) patients demonstrated partial response, 13 (46.4%) – stabilization and 7 – (25%) progressive disease. 1-, 2- and 3-survival rates were 34.7%, 15.2% and 11.6%, respectively. Two patients are still alive and under observation for 10 and 72 months. Median survival was 9.0 months in the general group and 12.0 months in the gemcitabin + mytomycin C group.
Conclusion. TACE is safe and effective procedure in management of non-surgical patients with peripheral cholnagiocarcinoma.
About the Authors
B. I. Dolgushin
FSBI N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Doct. of Med. Sci., Professor, RASci Corresponding Member, Head of Diagnostic and Interventional Radiology Department, N.N. Blokhin Russian Cancer Research Center
E. R. Virshke
FSBI N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Doct. of Med. Sci., Leading Researcher of Diagnostic and Interventional Radiology Department, N.N. Blokhin Russian Cancer Research Center
V. Yu. Kosyrev
FSBI N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Doct. of Med. Sci., Leading Researcher of Diagnostic and Interventional Radiology Department, N.N. Blokhin Russian Cancer Research Center
I. A. Trofimov
FSBI N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Interventional Radiologist of Diagnostic and Interventional Radiology Department, N.N. Blokhin Russian Cancer Research Center
A. V. Kukushkin
FSBI N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Cand. of Med. Sci., Interventional Radiologist of Diagnostic and Interventional Radiology Department, N.N. Blokhin Russian Cancer Research Center
V. A. Cherkasov
FSBI N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Cand. of Med. Sci., Senior Researcher of Diagnostic and Interventional Radiology Department, N.N. Blokhin Russian Cancer Research Center
O. N. Sergeeva
FSBI N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Cand. of Med. Sci., Researcher of Diagnostic and Interventional Radiology Department, N.N. Blokhin Russian Cancer Research Center
References
1. Aljiffry M., Walsh M.J., Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J. Gastroenterol. 2009; 15 (34): 4240–4262.
2. deJong M.C., Nathan H., Sotiropoulos G.C., Paul A., Alexandrescu S., Marques H., Pulitano C., Barroso E., Clary B.M., Aldrighetti L., Ferrone C.R., Zhu A.X., Bauer T.W., Walters D.M., Gamblin T.C., Nguyen K.T., Turley R., Popescu I., Hubert C., Meyer S., Schulick R.D., Choti M.A., Gigot J.F., Mentha G., Pawlik T.M. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J. Clin. Oncol. 2011; 29 (23): 3140–3145. doi: 10.1200/JCO.2011.35.6519.
3. Hyder O., Marsh J.W., Salem R., Petre E.N., Kalva S., Liapi E., Cosgrove D., Neal D., Kamel I., Zhu A.X., Sofocleous C.T., Geschwind J.F., Pawlik T.M. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann. Surg.Oncol. 2013; 20 (12): 3779–3786. doi: 10.1245/s10434-013-3127-y.
4. Ustundag Y., Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J. Gastroenterol. 2008; 14 (42): 6458–6466.
5. Chang K.Y., Chang J.Y., Yen Y. Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J. Natl. Compr. Cancer Netw. 2009; 7 (4): 423–427.
6. Welzel T.M., Graubard B.I., El-Serag H.B., Shaib Y.H., Hsing A.W., Davila J.A., McGlynn K.A. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin. Gastroenterol. Hepatol. 2007; 5 (10): 1221–1228.
7. Dhanasekaran R., Hemming A.W., Zendejas I., George T., Nelson D.R., Soldevila-Pico C., Firpi R.J., Morelli G., Clark V., Cabrera R. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol. Rep. 2013; 29 (4): 1259–1267. doi: 10.3892/or.2013.2290.
8. Endo I., Gonen M., Yopp A.C., Dalal K.M., Zhou Q., Klimstra D., D'Angelica M., DeMatteo R.P., Fong Y., Schwartz L., Kemeny N., O'Reilly E., Abou-Alfa G.K., Shimada H., Blumgart L.H., Jarnagin W.R. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann. Surg. 2008; 248 (1): 84–96.
9. Scheuermann U., Kaths J.M., Heise M., Pitton M.B., Weinmann A., Hoppe-Lotichius M., Otto G. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma – a single-center experience. Eur. J. Surg. Oncol. 2013; 39 (6): 593–600. doi: 10.1016/j.ejso.2013.03.010.
10. Park S.Y., Kim J.H., Yoon H.J., Lee I.S., Yoon H.K., Kim K.P. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin. Radiol. 2011; 66 (4): 322–328. doi: 10.1016/j.crad.2010.11.002.
11. Mosconi S., Beretta G.D., Labianca R., Zampinoc M.G., Gatta G., Heinemann V. Cholangiocarcinoma critical reviews in oncology. Hematology. 2009; 69 (3): 259–270. doi: 10.1016/j.critrevonc.2008.09.008.
12. Cho S.Y., Park S.J., Kim S.H., Han S.S., Kim Y.K., Lee K.W., Lee S.A., Hong E.K., Lee W.J., Woo S.M. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann. Surg. Oncol. 2010; 17 (7): 1823–1830. doi: 10.1245/s10434-010-0938-y.
13. Nakeeb A., Tran K.Q., Black M.J., Erickson B.A., Ritch P.S., Quebbeman E.J., Wilson S.D., Demeure M.J., Rilling W.S., Dua K.S., Pitt H.A. Improved survival in resected biliary malignancies. Surgery. 2002; 132 (4): 555–563.
14. Kim J.H., Yoon H.K., Sung K.B., Ko G.Y., Gwon D.I., Shin J.H., Song H.Y. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer. 2008; 113 (7): 1614–1622. doi: 10.1002/cncr.23787.
15. Vogl T.J., Naguib N.N., Nour-Eldin N.E., Bechstein W.O., Zeuzem S., Trojan J., Gruber-Rouh T. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. J. Cancer. 2012; 131 (3): 733–740. doi: 10.1002/ijc.26407.
16. Shimoda M., Kubota K. Multi-disciplinary treatment for cholangiocellular carcinoma. World J. Gastroenterol. 2007; 13 (10): 1500–1504.
17. Dodson R.M., Weiss M.J., Cosgrove D., Herman J.M., Kamel I., Anders R., Geschwind J.F., Pawlik T.M. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J. Am. Coll. Surg. 2013; 217 (4): 736–750. doi: 10.1016/j.jamcollsurg.2013.05.021.
18. Khan S.A., Thomas H.C., Davidson B.R., Taylor-Robinson S.D. Cholangiocarcinoma. Lancet. 2005; 366 (9493): 1303–1314.
19. Valle J., Wasan H., Palmer D.H., Cunningham D., Anthoney A., Maraveyas A., Madhusudan S., Iveson T., Hughes S., Pereira S.P., Roughton M., Bridgewater J. Cisplatin plus Gemcitabine versus Gemcitabine for biliary tract cancer. N. Engl. J. Med. 2010; 362 (14): 1273–1281. doi: 10.1056/NEJMoa0908721.
20. Ibrahim S.M., Mulcahy M.F., Lewandowski R.J., Sato K.T., Ryu R.K., Masterson E.J., Newman S.B., Benson A. 3rd, Omary R.A., Salem R. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008; 113 (8): 2119–2128. doi: 10.1002/cncr.23818.
21. Singal A.G., Rakoski M.O., Salgia R., Pelletier S., Welling T.H., Fontana R.J., Lok A.S., Marrero J.A. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol. Ther. 2010; 31 (6): 625–633. doi: 10.1111/j.1365-2036.2009.04218.x.
22. Liu R.Q., Shen S.J., Hu X.F., Liu J., Chen L.J., Li X.Y. Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors. Cancer Cell Int. 2013; 13 (1): 99. doi: 10.1186/1475-2867-13-99.
23. Ramirez-Merino N., Aix S.P., Cortes-Funes H. Chemotherapy for cholangiocarcinoma: An update. World J. Gastrointest. Oncol. 2013; 5 (7): 171–176. doi: 10.4251/wjgo.v5.i7.171.
24. Okusaka T., Nakachi K., Fukutomi A., Mizuno N., Ohkawa S., Funakoshi A., Nagino M., Kondo S., Nagaoka S., Funai J., Koshiji M., Nambu Y., Furuse J., Miyazaki M., Nimura Y. Gemcitabine alone or in combination with Cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br. J. Cancer. 2010; 103 (4): 469–474. doi: 10.1038/sj.bjc.6605779.
25. Demols A., Mare?chal R., Devie`re J., van Laethem J.L. The multidisciplinary management of gastrointestinal cancer. Biliary tract cancers: from pathogenesis to endoscopic treatment. Best Pract. Res. Clin. Gastroenterol. 2007; 21 (6): 1015–1029.
26. Park J., Kim M.H., Kim K.P., Park do H., Moon S.H., Song T.J., Eum J., Lee S.S., Seo D.W., Lee S.K. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver. 2009; 3 (4): 298–305. doi: 10.5009/gnl.2009.3.4.298.
27. Ortner M.A. Photodynamic therapy for cholangiocarcinoma. Lasers Surg. Med. 2011; 43 (7): 776–780. doi: 10.1002/lsm.21106.
28. Lee T.Y., Cheon Y.K., Shim C.S. Current status of photodynamic therapy for bile duct cancer. Clin. Endosc. 2013; 46 (1): 38–44. doi: 10.5946/ce.2013.46.1.38.
29. Liapi E., Geschwind J.F. Transcatheter and ablative therapeutic approaches for solid malignancies. J. Clin. Oncol. 2007; 25 (8): 978–986.
30. Kiefer M.V., Albert M., McNally M., Robertson M., Sun W., Fraker D., Olthoff K., Christians K., Pappas S., Rilling W., Soulen M.C. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer. 2011; 117 (7): 1498–1505. doi: 10.1002/cncr.25625.
Review
For citations:
Dolgushin B.I., Virshke E.R., Kosyrev V.Yu., Trofimov I.A., Kukushkin A.V., Cherkasov V.A., Sergeeva O.N. Transarterial Chemoembolization in Treatment of Inoperable Patients with Nodular Cholangiocarcinoma. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2015;20(3):24-30. (In Russ.) https://doi.org/10.16931/1995-5464.2015324-30
Views:
632
Email this article 